

**Wanbury Limited**

Regd. Office : BSEL Tech Park, B-wing  
10<sup>th</sup> Floor, Sector-30 A,  
Opp. Vashi Railway Station,  
Vashi Navi Mumbai 400 703  
Maharashtra, INDIA  
Tel. : +91-22-6794 2222  
+91-22-7196 3222  
Fax : +91-22-6794 2111/333  
CIN L51900MH1988PLC048455  
Email : info@wanbury.com  
Website : www.wanbury.com

November 22, 2025

BSE Limited PJ. Towers, Dalal Street Mumbai – 400 001. <b>Script Code: 524212</b>	National Stock Exchange of India Ltd, Exchange Plaza, Bandra Kurla Complex, Bandra (East), Mumbai – 400 051. <b>Script Code: WANBURY</b>
---	--

Dear Sir/Madam,

**Sub.: Disclosure under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 - Investors Presentation on Q2 & H1 FY26 Financial Results**

Please find attached herewith copy of Investors Presentation on Financial Results for the quarter and half year ended 30<sup>th</sup> September, 2025 and is also available on the website of the Company at [www.wanbury.com](http://www.wanbury.com).

This is for your information and record.

Thanking you.

Yours faithfully,  
**For Wanbury Ltd**



**Jitendra J. Gandhi**  
Company Secretary

Encl.: a/a.





Towards Better Healthcare

# Towards Better Healthcare

**Earnings Presentation**

Q2 & H1FY26 | November 2025

**Wanbury Limited**

**NSE: WANBURY | BSE: 524212**

**Bloomberg: WANB:IN**



# Inside this Presentation

## Company Profile



Executive Summary	04
Corporate Journey	05
Successful Business Turnaround	06
Wanbury at a Glance	07
Business Streams	08
Board of Directors	09
Senior Leadership	10
R&D Capabilities	11
Environment, Health & Safety	12

## Business Profile



<b>API Business</b>	
Strategically Curated Product Portfolio	14
World-Class Manufacturing Infrastructure	15
CAPEX Tracker	16
Developed Market Focused Business Profile	17
Regulatory Approvals	18
Manufacturing Capabilities	19
Strategy & Way Forward	20
Safety First Culture	21



<b>Formulations Business</b>	
Re-Building Business	23
Brand Portfolio	24
Strategy & Way Forward	25

## Q2 & H1FY26 Earnings Update



Performance Highlights	27
Business Verticals Performance	28
P&L Snapshot	29
Management Commentary	30

## Financial Profile



Key Performance Indicators	32
5Y P&L Snapshot	33
5Y Balance Sheet Snapshot	34
5Y Cash Flow Snapshot	35
Capital Markets Overview	36



# 01


## Company Profile

Executive Summary	04
Corporate Journey	05
Successful Business Turnaround	06
Wanbury at a Glance	07
Business Streams	08
Board of Directors	09
Senior Leadership	10
R&D Capabilities	11
Environment, Health & Safety	12




# Executive Summary

## Successful turnaround to growth momentum




Operational & financial turnaround over last 2 years, now transforming into growth momentum

## Global market leaderships in key products



Globally significant market share in Metformin & Sertraline

## Building new growth drivers in API business



Through launch of an Anaesthetic in Q4, and pipeline of 4 molecules commercialisation each year beginning next financial year

## De-risked & robust balance sheet



Refinanced debt & healthy internal accruals i.e. moderate leverage ratio of ~2X Debt/EBITDA

## Established global regulatory approvals




## Levers for operating leverage & margin expansion



Through brownfield expansion, operational scale-up, and borrowing cost optimisation

## Formulation growth story



Turnaround, envisaged break-even (in FY26), to rebuilding & scale-up (in FY27)

# Corporate Journey

## 1990-2000

### Foundation & Early Strategic Acquisitions

#### 1990

Incorporated as Pearl Organics Pvt. Ltd.

#### 1992

Established 1<sup>st</sup> plant for manufacturing APIs

#### 1995

Acquired Brij Chemicals' plant at Patalganga (Maharashtra)

#### 1995

Acquired Wander Limited → a subsidiary of Sandoz (Brand Formulation Business)

#### 1996

Formed a strategic alliance with Wyckoff Chemicals (US) to market APIs in US

## 2000-2010

### Corporate Consolidation & Venture into Developed Markets

#### 2002

USFDA approval received for Patalganga plant

#### 2004

Wander Limited merged with Pearl Organics Limited → Renamed Wanbury Limited

#### 2006

Acquired Doctor's Organic and Chemicals Limited (DOCL) with a multi-purpose USFDA-approved facility in Tanuku

#### 2007

- DOCL merged with Wanbury Limited
- Listing on NSE & BSE
- Acquired Cantabria Pharma S.L. (Spain) - Present in ethical branded formulations in European market

## 2010-2023

### Challenges & Business Turnaround

Underwent Corporate Debt Restructuring with Banks

#### 2020

Deleveraged through strategic sale of brands to Cipla worth ₹87 crore

#### 2021

Capital infusion of ₹50 crore through Preferential Issue

#### 2023

- Raised ₹95 crore via NCD from Neo AIF
- Settlement with all the lenders

## 2024-Onwards

### Transformation & Growth

#### 2024

Scale up EBITDA to ₹73 crore

#### 2025

- Modernised the facilities with an investment of ₹48 crore
- 6<sup>th</sup> successful USFDA inspection for Patalganga plant (zero 483 observations)
- Successful ANVISA audit clearance for Tanuku plant
- Refinanced Neo AIF Debt at lower interest rate
- Achieved highest-ever Operational EBITDA of ₹80 crore

# Successful Business Turnaround

## Financial Turnaround



Debt reduction: **~75% reduction from peak-debt obligation of ~700 Crores**, including corporate guarantee from Wanbury Limited to Wanbury Holding B.V. (Netherlands) for foreign debt held by Netherlands subsidiary



Debt refinancing: **Reduction in borrowing cost from 22.5% to 12.5% with effected from 1<sup>st</sup> March 2025**, with scope for further reduction in coming years



**Exited all high cost private financial agreements**

## Operational Turnaround



**Capacity ramp-up in key existing API products through de-bottlenecking:**  
Metformin (25% increase in last 3 years)  
& Sertraline (20% increase in last 3 years)



Operational profitability: **~3X EBITDA scale-up between FY23-FY25**, through de-bottlenecking projects & production scale-up, efficient procurement practises, technical savings, among others



**Envisaged break-even profitability in Formulations business**, delivered financial break-even in H1 FY26



# Wanbury at a Glance



**6 products,  
100% chronic  
portfolio**

API Portfolio



**10+ brands,  
acute &  
semi-chronic**  
Formulations Portfolio



**2 USFDA  
approved API  
facilities**  
with 386 KL cumulative  
reactor capacity



**80%+**  
Export top line, with  
emphasis on developed  
markets



**1,200+**  
Employee strength




**37+ years**  
Operating history



**Regulatory  
Approvals**



**Dual revenue-stream**



■ API ■ Formulation





# Business Streams

## API



API manufacturer building a niche, profitable & sustainable business (50%+ Gross contribution margins)

Diversified business stream across 6 products + additional launches in pipeline


Regulatory markets focused (EU, Brazil, US) mature & sustainable API business

**₹530 Crore+**

FY25 Revenue

**₹282 Crore+**

H1FY26 Revenue



● API

● Formulations

## Formulations



Rebuilding legacy brand formulations business in India

10+ active brands + additional launches in pipeline

Key therapeutic categories such as Anti cold & cough, Anti-infective, Anti-inflammatory, Supplements, Orthopaedic, among others

**₹70 Crore+**

FY25 Revenue

**₹41 Crore+**

H1FY26 Revenue

# Board of Directors



**Mr. Mohan Kumar Rayana**

Promoter & Whole Time Director

25+ years of experience

He holds a Bachelor of Pharmacy from the University of Mumbai and brings over 30 years of diverse experience in the pharmaceutical industry. He has led the company's growth since inception, overseeing strategic acquisitions and operational expansion.



**Mr. K. Chandran**

Whole Time Director

30+ years of experience

He graduated with a Bachelor of Science from the University of Mumbai and has over 28 years of pharmaceutical sector experience. Mr. Chandran has played a key role in the company's strategic direction and has been associated with Wanbury for more than 25 years.



**Dr. Anupama Vaidya**

Non Executive Independent Woman Director

30+ years of experience

She holds a Bachelor's degree in Computer Science from the University of Pune as well as an MBA specializing in Human Resource Development from Symbiosis Institute of Business Management, Pune. She brings a strong background in technology and HR development to the board.



**Mr. Mridul Mehta**

Non Executive Independent Director

30+ years of experience

He holds a BE in Computer Science from Maharaja Sayajirao University Baroda and an MBA in Finance from the Indian Institute of Management (IIM), Bangalore. With more than 30 years of professional experience, Mr. Mehta specializes in business strategy, management consulting, investment banking, and finance.



**Mr. Manoj Gursahani**

Non Executive Independent Director

35+ years of experience

He serves as the Executive Director of the Mumbai-Global Chamber and is Co-Founder of Vera Healthcare Technologies, an AI-driven platform for early screening and detection of Diabetic Retinopathy, Glaucoma, and Age-Related Macular Degeneration. He brings significant leadership experience from the healthcare and technology sectors.



**Mr. Pallavur Sankar Das**

Non Executive Independent Director

35+ years of experience

He is an accomplished leader with more than 35 years of experience in the pharmaceutical industry. He has built and scaled businesses across India and other emerging markets. From 2014 to 2022, he was CEO and Director of Curatio Healthcare Private Limited, a domestic dermatology and cosmetic pharmaceutical company.

# Senior Leadership



**Mr. Vinod Verma**

Chief Financial Officer

30+ years of experience

Mr. Vinod Verma is a qualified Chartered Accountant and Company Secretary with over 30 years of comprehensive experience in finance, taxation, audit, and management consultancy. He has held senior leadership roles across prominent organizations, including Escorts, Raymond, and JSW, contributing his expertise to diverse industry sectors.



**Mr. Prakash Venkatraman**

President – API Business

30+ years of experience

Mr. Prakash Venkatraman is a Chemical Engineer with a Master's in Management Studies from Mumbai University, bringing over 30 years of leadership in API operations, business strategy, and P&L management. Before joining Wanbury, he led the API division at Shilpa Pharma Lifesciences, managed a \$175 million global API portfolio at Sun Pharma, and scaled Jubilant Life Sciences' API business to \$105 million. His career also includes key roles at Wockhardt, Ranbaxy, and Kopran.



**Mr. Rashesh Patel**

President – India Formulations Business

35+ years of experience

Mr. Rashesh Patel possesses more than 35 years of experience in pharmaceutical sales, marketing, and business transformation. He has served as Director at Kepler Healthcare and has held key leadership roles in renowned pharmaceutical companies such as Torrent, Emcure, Troikaa Pharmaceuticals, Astra ID, and Panacea Biotech. Notably, Mr. Patel drove the scale-up of Corona Remedies from three partially operational units to six pan-India divisions, significantly improving its market position from rank 107 to 36 (AWACS).



# R&D Capabilities



API R&amp;D Center



## Location

Tanuku, Andhra Pradesh



## DSIR and FDA (India)

Recognized

### R&D Competencies

- New API development
- Cost optimization for existing molecules
- Troubleshooting plant problems
- Analytical development
- Process optimization
- Backward integration development

### Immediate Focus Areas:

- Sertraline backward integration
- Metformin yield improvement
- New molecule commercialization's (4 annually)
- Patented molecules process development (post-FY29 focus area)



Formulations R&amp;D Center



## Location

Navi Mumbai, Maharashtra



## DSIR and FDA (India)

Recognized

### R&D Competencies

- Cost optimizations
- New product development
- Process technology development
- Development of Novel Platforms for Speciality Generics and Intellectual Property Rights (IPR)

## R&D Capabilities



### Process Optimization:

Optimization of synthesis routes for enhanced yields & lowering costs



### Impurity Control:

Advanced analytical techniques aligned with ICH guidelines



### Analytical Excellence:

DSIR-approved R&D facility with validated methods



### Green Chemistry:

Integration of sustainable solvents, catalysis, and waste reduction efforts



### Scale-Up Capability:

Lab to commercial with FTE team, integrated QC lab

# Environment, Health & Safety

## EHS at Wanbury

- **Best-in-class standards:** Committed to global EHS norms and strict regulatory compliance across all operations
- **Environmental focus:** Zero liquid discharge (ZLD) plants, advanced Effluent Treatment Plants (ETP), and continual investment in energy efficiency
- **Sustainable energy:** Upcoming 1.5 MW solar energy project at Satara, to meet 70% of Patalganga site's energy requirements captively through renewable energy
- **Safety culture:** Comprehensive training, systematic risk assessments (HAZOP), and robust emergency response systems at all sites
- **Community & workforce:** Prioritizing safety, public health, and sustainability for employees and local communities






# 02

## Business Profile: API

Strategically Curated Product Portfolio	14
World-Class Manufacturing Infrastructure	15
CAPEX Tracker	16
Developed Market Focused Business Profile	17
Regulatory Approvals	18
Manufacturing Capabilities	19
Strategy & Way Forward	20
Safety First Culture	21





# API: Strategically Curated Product Portfolio

## Significant global market share in Top 3 products

Molecule	Therapeutic Category	Global Market (MT)	Estimated Market Share
Metformin	Antidiabetic	~75,000	~11%
Sertraline	Antidepressant	~680	~30%
Tramadol	Pain Management	~550	~11%

## Existing portfolio – 6 molecules


- Metformin - Antidiabetic
- Sertraline - Antidepressant
- Tramadol - Pain Management
- Paroxetine - Antidepressant
- Mefenamic acid - Anti-inflammatory
- Diphenhydramine - Antihistamine

## Upcoming portfolio – 1 molecule


- An Anaesthetic  
(Planned commercialisation in Q4FY26)
- 4 new additions each year beginning FY27

Note - Market Size, Market Share data as per Clarivate & Company Estimates

## API - Revenue & Share



## API Sales Breakdown



# API: World-Class Manufacturing Infrastructure

## Site 1: Tanuku, Andhra Pradesh



**400 KL**

Reactor Capacity



**~70%**

Revenue Contribution



**450+**

Headcount



**18 Acres**

Land Bank

### Multi-Purpose Plant

Metformin, Sertraline,  
Tramadol, Paroxetine,  
Mefenamic Acid,  
Diphenhydramine,  
(upcoming  
anaesthetic)

**Potential for future  
brownfield CAPEX**

## Site 2: Patalganga, Maharashtra



**96 KL**

Reactor Capacity



**~30%**

Revenue Contribution



**250+**

Headcount



**2.3 Acres**

Land Bank

### Dedicated Plant

Metformin, Metformin DC

**Fully-occupied  
at present**


Cumulative installed  
reactor capacity:

**500 KL**

Future reactor capacity  
potential at existing sites:

**600 KL**

# API: CAPEX Tracker





# API: Developed Market Focused Business Profile



Focused on  
regulated markets




Exporting to  
**50+**  
countries



Exporting to  
**4+**  
continents

## Total Revenue Mix



■ Exports   ■ Domestic



Map not to scale, only for illustration purpose.

# API: Regulatory Approvals

## US-FDA

**US – FDA**  
Approval since **2000**  
Last inspection **2024**



**Europe – EDQM**  
Approval since **2007**  
Last inspection **2014**



**Brazil – ANVISA**  
Approval since **2024**  
Last inspection **2024**



**South Korea – KFDA**  
Approval since **2012**  
Last inspection **2012**



**Mexico – COFEPRIS**  
Approval since **2013**  
Last inspection **2013**



**WHO GMP**  
Approval since **2007**  
Last inspection **2025**



**WHO GMP**  
Approval since **2013**  
Last inspection **2025**

## DMF/CEP Filings with Global Regulatory Authorities

	Approved	Under Review & Pending	Total
USA	22	-	22
Europe	8	1	9
Brazil	1	5	6
South Korea	3	-	3
Mexico	-	-	-
ROW	30	-	30
<b>Total</b>	<b>64</b>	<b>6</b>	<b>70</b>

# API: Manufacturing Capabilities

## Chemistry Capabilities



- Azidation
- Bromination
- Cyanation
- Chiral Chemistry
- Optical Resolution
- Demethylation
- Grignard Reaction
- Sodium Metal Reactions
- Metal Hydride Reductions
- Friedel-Crafts Reactions
- Nitration
- Reductions
- Hydrogenation

## Reaction Capabilities



- High Pressure Reactions
- High Vacuum Distillations
- Direct Compression (DC) Grade
- Manufacturing Different Polymorphisms
- Hydrated Molecules
- Handling Hygroscopic Products

## System Capabilities



- Deployed SAP S4 HANA
- Dedicated software for Sales & Distribution functions
- Dedicated software for Fleet-on-Street
- Dedicated platforms used for sourcing & procurements
- Dedicated solutions for QC management



# API: Strategy & Way Forward

## Way Forward



Targeted expansion in regulated markets (US, EU, Brazil) – new & existing molecules



4 commercial launches of new molecules each year beginning FY27



Focus on a mix of:  
a) High-value or  
b) Large-volume + sizable market share molecules



Target patented molecules supply chain beyond FY29-30



Deploy backward integration selectively to optimize inputs cost & improve contribution margins



## Product Selection Framework

### Mid-Size Molecules

Small-to-Mid size molecules + Aim double-digit market share

### Client Fit

Favour APIs requested by current marquee clientele

### Margin Profile

Aim for ~50% gross margins

# API: Safety First Culture






# 03

## Business Profile: Formulations

Re-Building Business	23
Brand Portfolio	24
Strategy & Way Forward	25



# Formulations: Re-Building Business

## Overview

- Formulations business journey commenced in 1995 with the acquisition of Wander Ltd, formerly a division of Sandoz
- Current portfolio is focused on therapeutics such as anti-cold & cough, anti-infective, anti-inflammatory, analgesic, antipyretic, orthopaedic and constipation medications, as well as protein supplements, multivitamins, and multimineral supplements
- Operating through a fully outsourced manufacturing model, enabling enhanced scalability and flexibility
- Strategic emphasis remains on building strong brands & distribution channels, driven by a dedicated business excellence team



**10+**

Brands

**100%**

Acute Therapy

**300+**

Field Force

**30,000+**

Doctors Engaged


**17**

C&F Agents


**1,800+**

Distributors

## Formulations - Revenue & Share



## Revenue Mix – Top Brands





# Formulations: Brand Portfolio

## Top brands

**Coriminic®**

Anti Cold & Cough



**Chymonac™**

Pain & Inflammation,  
Muscular Spasm



**RabiPlus™**

Antacids & Anti-ulcerants



**Senasof™**

Herbal Laxative



**Nurture®**

Protein Supplement



**ADTROL**

Calcium Supplement -  
Osteoporosis & Bone Health



**WANBURY  
C RED**

Nutritional Supplement



**Zeva™**

Multivitamin Supplement



# Formulations: Strategy & Way Forward

## Operational Objectives

### 1 Latest brand launch (FY25)

C RED (Iron Supplement)

### 2 Upcoming therapeutic launches

Paediatrics, Dermatology: Better right-to-win through existing brand equity with Paediatricians

Cardiology & Diabetes: Launching chronic & speciality products to improve productivity & add portfolio diversity

Speciality Segments: Building presence across GYN/PED/CP/ORTHO/SUR segments

### 3 Planned geographic expansion

Expansion into newer attractive regions

Increasing field force for existing regions

## Strategic Way Forward



Leverage 3+ decades of heritage to re-build a scalable branded formulations franchise



Transition portfolio from acute therapeutics towards speciality and chronic segments through new launches



Geographical expansion in newer attractive markets



Achieve profitability break-even in FY26 through better scale & cost-management efforts



Deliver sustainable profitability FY27 onwards, through: Scaling top brands, launching new therapies, increasing front-line doctor engagement

# 04


## Q2 & H1 FY26 Earnings Update

Performance Highlights	27
Business Vertical Performance	28
P&L Snapshot	29
Management Commentary	30




# Q2 & H1FY26 Performance Highlights


## Revenue (in ₹ Crore)



## EBITDA (in %)



## PAT (in ₹ Crore)






# Business Vertical Performance

## API - Revenue (in ₹ Crore)




-5.0%

QOQ GROWTH



8.2%

YOY GROWTH




## Formulations - Revenue (in ₹ Crore)




22.2%

QOQ GROWTH



17.6%

YOY GROWTH



# Q2 & H1FY25 P&L Snapshot

PARTICULARS (in ₹ Crore)	Q2FY25	Q1FY26	Q2FY26	YOY Change	QOQ Change	H1FY25	H1FY26	YOY Change
<b>Revenue from Operations</b>	161.19	163.18	160.06	-1%	-2%	292.3	323.2	10.57%
Other Income	1.63	0.35	0.20	-88%	-42.86%	2.58	0.55	-78.68%
COGS	82.02	75.35	67.06	-18%	-11.00%	148.27	142.40	-3.96%
<b>Gross Profit</b>	<b>80.80</b>	<b>88.18</b>	<b>93.20</b>	15%	<b>5.69%</b>	<b>146.61</b>	<b>181.35</b>	23.70%
<b>Gross Margin (%)</b>	<b>50.13%</b>	<b>54.04%</b>	<b>58.23%</b>	<b>16%</b>	<b>7.75%</b>	<b>50.16%</b>	<b>56.11%</b>	11.87%
Operating Expenses	59.16	63.40	67.22	14%	<b>6.03%</b>	113.04	130.62	15.55%
<b>EBITDA</b>	<b>21.64</b>	<b>24.79</b>	<b>25.98</b>	<b>20%</b>	<b>4.81%</b>	<b>33.56</b>	<b>50.77</b>	51.26%
<b>EBITDA Margin (%)</b>	<b>13.42%</b>	<b>15.19%</b>	<b>16.23%</b>	<b>21%</b>	<b>6.85%</b>	<b>11.48%</b>	<b>15.71%</b>	36.80%
Finance Cost	10.15	7.54	7.12	-30%	-5.57%	17.74	14.66	-17.36%
Depreciation	3.32	3.64	3.70	11%	1.65%	6.61	7.34	11.04%
<b>Profit before Tax</b>	<b>8.17</b>	<b>13.61</b>	<b>15.16</b>	<b>86%</b>	11.41%	<b>9.21</b>	<b>28.77</b>	212.22%
<b>Profit after Tax</b>	<b>8.02</b>	<b>13.49</b>	<b>15.18</b>	<b>89%</b>	12.53%	<b>9.06</b>	<b>28.67</b>	216.45%
<b>PAT Margins (%)</b>	<b>4.98%</b>	<b>8.27%</b>	<b>9.48%</b>	<b>91%</b>	14.72%	<b>3.10%</b>	<b>8.87%</b>	186.19%
<b>Basic EPS (in ₹)</b>	<b>2.44</b>	<b>4.12</b>	<b>4.58</b>	<b>88%</b>	11.17%	<b>2.76</b>	<b>8.70</b>	215.22%

# Management Commentary



**Mr. Mohan Kumar Rayana**

Promoter & Whole Time Director

Q2 continues to be stronger with EBITDA achievement of ₹ 26.0 (16.2%) crore as compared to ₹21.6 (13.3%) crore in Q2 FY25, registering a growth of 20% over previous quarter, overall improvement of 292 bps of revenues. Further, achieved PAT of ₹ 15.2 crore as compared to ₹ 8.0 crore in Q2 FY25, registering a robust growth of approx. 90 % led by cost efficiencies, improved Product yield & lower finance cost.

This improvement was driven by several technical initiatives including enhanced product yields and higher solvent recoveries. Additionally, contributed by procurement efficiencies—such as improved negotiations through auction-based sourcing for large-volume raw materials and longer period suppliers' contracts for KSM.

The Company's Formulations business turned EBITDA positive supported by the successful launch of the new brand (C-red-advanced liposomal iron supplement), overall improved field productivity across Brands through targeted training of the sales force and various brand promotion activities.


The recent implementation of the SAP S/4HANA Private Cloud under the Rise with SAP initiative marks a significant milestone in our digital transformation journey. This will enable greater agility, operational transparency, and data-driven decision-making across the organization.

With our CAPEX plan on its way for introduction of new products, we remain committed to sustainable growth, increasing capacities, sustaining operational efficiencies and maintaining the highest standards of quality and compliance. Our efforts are aimed at strengthening Wanbury's position as a trusted global pharmaceutical partner while driving long-term value for all stakeholders.

# 05

## Financial Profile

Key Performance Indicators	32
5Y P&L Snapshot	33
5Y Balance Sheet Snapshot	34
5Y Cash Flow Snapshot	35
Capital Markets Overview	36






# Key Performance Indicators


## Revenue from Operations

(in ₹ Crore)




## Gross Profit & Gross Margins

(in ₹ Crore &amp; in %)




## EBITDA & EBITDA Margins

(in ₹ Crore &amp; in %)




## PAT & PAT Margins

(in ₹ Crore &amp; in %)




## Working Capital Days

(in Days)




## ROCE

(in %)



## ROE

(in %)



# 5Y P&L Snapshot

PARTICULARS (in ₹ Crore)	FY21	FY22	FY23	FY24	FY25	H1 FY26
Revenue from Operations	392.5	511.2	499.7	575.7	599.51	323.2
Other Income	2.4	1.51	0.91	2.99	3.49	0.55
COGS	221.3	300.3	303.4	302.6	294.47	142.4
Gross Profit	173.6	212.4	197.1	276	308.53	181.35
Gross Margin (%)	44%	42%	39%	48%	51%	56%
Operating Expenses	153.2	175.6	173	203	228.73	130.62
EBITDA	20.42	36.84	24.09	72.99	79.81	50.77
EBITDA Margin (%)	5%	7%	5%	13%	13%	16%
Finance Cost	23.07	20.61	21.4	29.18	36.95	14.66
Depreciation	9.75	11.45	12.38	13.03	13.31	7.34
Exceptional Item	-	76.37	-0.6	-	-	-
Profit before Tax	-12.4	81.13	-9.69	30.78	29.55	28.77
Profit after Tax	-12.61	81.47	-10.4	30.4	30.53	28.67
PAT Margins (%)	-3%	16%	-2%	5%	5%	9%
Basic EPS (in ₹)	-5.04	25.29	-3.18	9.29	9.32	8.7

# 5Y Balance Sheet Snapshot

PARTICULARS (in ₹ Crore)	FY21	FY22	FY23	FY24	FY25	H1 FY26
<b>Equity Share Capital</b>						
Equity Share Capital	25.01	32.67	32.7	32.74	32.77	34.88
Other Equity	-155.7	-30.48	-39.96	-4.8	26.5	72.35
<b>Non-Current Liabilities</b>						
Long Term Borrowings	71.99	-	-	82	160.29	143.94
Others	18.07	16.2	16.31	19.45	19.74	20.17
<b>Current Liabilities</b>						
Short Term Borrowings	88.43	67.02	64.14	27.27	12.94	50.02
Trade Payables	133.27	191.1	148.2	162.8	138.46	112.53
Advances from customers	3.32	14.92	9.27	2.78	2.97	3.85
Others	103.18	59.54	71.58	20.93	20.25	18.82
<b>Total Equity and Liabilities</b>	<b>287.6</b>	<b>351</b>	<b>302.2</b>	<b>343.1</b>	<b>413.92</b>	<b>456.56</b>
<b>Non-Current Assets</b>						
Tangible Assets	158.11	148.7	151.5	149	189.69	189.6
CWIP	11.01	2.35	1.61	3	5.38	13.39
Others	22.53	30.24	28.59	32.19	25.4	29.84
<b>Current Assets</b>						
Inventories	24.85	49.73	21.99	36.02	37.68	46.37
Trade Receivables	34.47	62.8	68.98	89.44	114.16	127.36
Current Investments	-	-	-	-	-	-
Cash & Bank Balances	11.66	25.27	3.89	5.9	12.83	9.29
Others	24.97	31.9	25.68	27.55	28.78	40.71
<b>Total Assets</b>	<b>287.6</b>	<b>351</b>	<b>302.2</b>	<b>343.1</b>	<b>413.92</b>	<b>456.56</b>


# 5Y Cash Flow Snapshot

PARTICULARS (in ₹ Crore)	FY21	FY22	FY23	FY24	FY25	H1 FY26
<b>Cash Flow from Operating Activities</b>	16.68	37.56	19.8	4.02	26.1	-5.66
Cash Flow from Investing Activities	8.04	0.59	-8.84	-16.62	-51.17	-15.27
Cash Flow from Financing Activities	-17.38	-25.62	-31.99	14.55	25.73	21.34
<b>Net Cash Flows</b>	<b>7.34</b>	<b>12.53</b>	<b>-21.03</b>	<b>1.95</b>	<b>0.66</b>	<b>0.42</b>
Cash at the Beginning of Year	2.62	9.96	22.49	1.45	3.4	4.06
Cash at the End of Year	<b>9.96</b>	<b>22.49</b>	<b>1.46</b>	<b>3.4</b>	<b>4.06</b>	<b>4.48</b>



# Capital Markets Overview

Shareholding Pattern (%)



Shareholding data as of 30<sup>th</sup> September 2025

Current Market Price	₹230
52 Week High/Low	₹330 / ₹154
Market Capitalization	₹800 Crore
No. of Shares Outstanding	3.49 Crore
NSE	WANBURY
BSE	524212

Market price data as of 21<sup>st</sup> November 2025

# Get in Touch

This document which has been prepared by Wanbury Limited ("Wanbury" or "the Company"), has been prepared solely for information purposes. This document has been prepared by the Company based on information and data which the Company considers reliable, but the Company makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this Document. This Document may not be all inclusive and may not contain all of the information that you may consider material. Any liability in respect of the contents of, or any omission from, this Document is expressly excluded.

Certain matters discussed in this Document may contain statements regarding the Company's market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. These risks and uncertainties include, but are not limited to, the performance of the Indian economy and of the economies of various international markets, the performance of the industry in India and world-wide, competition, the company's ability to successfully implement its strategy, the Company's future levels of growth and expansion, technological implementation, changes and advancements, changes in revenue, income or cash flows, the Company's market preferences and its exposure to market risks, as well as other risks. The Company's actual results, levels of activity, performance or achievements could differ materially and adversely from results expressed in or implied by this Document. The Company assumes no obligation to update any forward-looking information contained in this Document. Any forward-looking statements and projections made by third parties included in this Document are not adopted by the Company and the Company is not responsible for such third-party statements and projections.



Towards Better Healthcare

**Wanbury Limited**

**Vinod Verma**

Chief Financial Officer

[investor@wanbury.com](mailto:investor@wanbury.com)

[investorrelations@wanbury.com](mailto:investorrelations@wanbury.com)



**TIL Advisors Private Limited**

**Sayam Pokharna**

Investor Relations Advisor

[sayam@theinvestmentlab.in](mailto:sayam@theinvestmentlab.in)